Your Unread Messages in Pharmacy
See All >> Messages include industry-sponsored communications and special communications from MDLinx
D Scott Cunningham MD, PhD
Site Editor, MDLinx
ASA as effective as sumatriptan in treatment of acute migraines
Jill Baker
MDLinx Career Center
NPs and PAs play crucial role amid PCP shortage
Smartest Doc Challenge
MDLinx
Clinical Pearls for Pain Managers and Prescribers
MDLinx Reminder
MDLinx
Conference Center Upgraded with New Tools
MDLinx Top Read
MDLinx
Running from that pile of unread journals?
1 FDA Drug Safety Communication: FDA approves label changes for zolpidem products, including new dosing and a recommendation to avoid driving the day after Ambien CR use Full Text FDA What's New: Drugs, May 17, 2013
2 Rotavirus vaccine developed in India shows positive results Full Text American Pharmacists Association News, May 17, 2013
3 FDA approves Nymalize--first nimodipine oral solution for use in certain brain hemorrhage patients Full Text FDA Press Announcements, May 17, 2013
4 FDA approves first companion diagnostic to detect gene mutation associated with a type of lung cancer Full Text FDA Press Announcements, May 17, 2013
5 FDA approves new drug for advanced prostate cancer Full Text FDA Press Announcements, May 17, 2013
6 FDA approves Tarceva (erlotinib) tablets and cobas EGFR Mutation Test for specific type of lung cancer Full Text Roche, May 16, 2013
7 Ranibizumab: The First Vascular Endothelial Growth Factor Inhibitor Approved for the Treatment of Diabetic Macular Edema Annals of Pharmacotherapy, May 13, 2013 Review Article
8 Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) Now Approved in the US for Maintenance Treatment in Children and Adolescents with ADHD Full Text Shire, May 10, 2013
9 FDA Approves Mercks LIPTRUZET (ezetimibe and atorvastatin), a New Product That Can Help Powerfully Lower LDL Cholesterol Full Text Merck, May 8, 2013
10 Adherence Associated with Oral Medications in the Treatment of Spasticity PM&R, May 8, 2013 Clinical Article
11 Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar(R) / Prolopa(R) Full Text BMC Pharmacology & Toxicology, May 7, 2013 Clinical Article
12 Regulatory and Scientific Issues Regarding Use of Foreign Data in Support of New Drug Applications in the United States: An FDA Perspective Clinical Pharmacology & Therapeutics, May 6, 2013 Clinical Article
13 New treatment options for castration-resistant prostate cancer American Journal of Health-System Pharmacy, May 3, 2013 Clinical Article
14 Rivoglitazone: A New Thiazolidinedione for the Treatment of Type 2 Diabetes Mellitus Annals of Pharmacotherapy, May 2, 2013 Clinical Article
15 Canagliflozin: First in class for type 2 diabetes Full Text American Pharmacists Association News, May 2, 2013
16 Dimethyl fumarate: Oral option for MS Full Text American Pharmacists Association News, May 2, 2013
17 Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma Full Text Merck, April 29, 2013
18 Mycophenolate Fetal Toxicity and Risk Evaluation and Mitigation Strategies American Journal of Transplantation, April 29, 2013 Review Article
19 CHMP recommends conditional EU approval of Roche's Erivedge for advanced basal cell carcinoma, a rare but potentially devastating form of skin cancer Full Text Roche, April 29, 2013
20 Systematic Review of CETP Inhibitors for Increasing High-Density Lipoprotein Cholesterol: Where Do These Agents Stand in the Approval Process? American Journal of Therapeutics, April 24, 2013 Evidence Based Medicine Review Article
Indexed Journals in Pharmacy: Expert Opinion in Pharmacotherapy, Formulary, U.S.Pharmacist more
Register now to view all the MDLinx contents (FREE)!
Login
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close